ReviewJournal of medical toxicology : official journal of the American College of Medical Toxicology2020
COVID-19: Therapeutics and Their Toxicities.
Review in Journal of medical toxicology : official journal of the American College of Medical Toxicology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 64 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
64 citing papers in PubMed, 1 synthesis or guideline pooled it, 118 citations in OpenAlex.
- The Outcome of Hydroxychloroquine in Patients Treated for COVID-19: Systematic Review and Meta-Analysis.Canadian respiratory journal · 2020Pooled it
- Monocyte chemoattractant protein-1 (MCP-1/CCL2) and matrix metalloproteinase-9 (MMP-9) as biomarkers of disease severity in COVID-19 patients.Biochemistry and biophysics reports · 2026Article
- Hydroxychloroquine: A double‑edged sword (Review).Molecular medicine reports · 2025Review
- A Concise Review of Major Challenges in the Vaccination, Diagnosis and Treatment of Novel Coronavirus Disease 2019.Archives of Razi Institute · 2024Review
- COVID-19: vaccination, therapeutics and a review of the science and public health.Annals of medicine and surgery (2012) · 2024Review
- Acute Poisoning Among Children Admitted to Alexandria Poison Center, Egypt: Patterns and Predisposing Factors.Cureus · 2024Article
- Blood ACE2 Protein Level Correlates with COVID-19 Severity.International journal of molecular sciences · 2023Article
- The role of emergency physicians in the fight against health misinformation: Implications for resident training.AEM education and training · 2023Article
- Importance of Magnesium Status in COVID-19.Biology · 2023Review
- COVID-19 Therapeutics: Use, Mechanism of Action, and Toxicity (Vaccines, Monoclonal Antibodies, and Immunotherapeutics).Journal of medical toxicology : official journal of the American College of Medical Toxicology · 2023Review
- COVID-19 Therapeutics: Use, Mechanism of Action, and Toxicity (Xenobiotics).Journal of medical toxicology : official journal of the American College of Medical Toxicology · 2023Review
- Necessary to Identify Latent Toxicants Associated with COVID-19.International journal of preventive medicine · 2023Article
- Article
- Site-Directed Spin Labeling EPR Spectroscopy for Determination of Albumin Structural Damage and Hypoalbuminemia in Critical COVID-19.Antioxidants (Basel, Switzerland) · 2022Article
- Manzamine-A Alters In Vitro Calvarial Osteoblast Function.Marine drugs · 2022Article
- A comprehensive review of adverse events to drugs used in COVID-19 patients: Recent clinical evidence.European journal of clinical investigation · 2022Review
- Hydroxychloroquine and Chloroquine Toxicity as Reported by Medical Toxicologists to the Toxicology Investigators Consortium (ToxIC) Registry.Journal of medical toxicology : official journal of the American College of Medical Toxicology · 2022Article
- Human Superantibodies to 3CLInternational journal of molecular sciences · 2022Article
- Optimizing antiviral therapy for COVID-19 with learned pathogenic model.Scientific reports · 2022Article
- Pathogenesis of vaccine-induced immune thrombotic thrombocytopenia (VITT).Seminars in hematology · 2022Article
4 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 4 institutions in 1 country.
Funding
Abstract
SARS-CoV-2 is a novel coronavirus that emerged in 2019 and is causing the COVID-19 pandemic. There is no current standard of care. Clinicians need to be mindful of the toxicity of a wide variety of possibly unfamiliar substances being tested or repurposed to treat COVID-19. The United States Food and Drug Administration (FDA) has provided emergency authorization for the use of chloroquine and hydroxychloroquine. These two medications may precipitate ventricular dysrhythmias, necessitating cardiac and electrolyte monitoring, and in severe cases, treatment with epinephrine and high-doses of diazepam. Recombinant protein therapeutics may cause serum sickness or immune complex deposition. Nucleic acid vaccines may introduce mutations into the human genome. ACE inhibitors and ibuprofen have been suggested to exacerbate the pathogenesis of COVID-19. Here, we review the use, mechanism of action, and toxicity of proposed COVID-19 therapeutics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.